A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases

Completed · Phase 1 · Has a placebo group

Conditions studied: Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc

In brief

To evaluate the safety and tolerability of escalating, single subcutaneous doses of MEDI7734 in adult subjects with type I interferon-mediated autoimmune diseases.

Key facts

Study ID

NCT02780674

Run by

Amgen

People needed

36

Starts

2016-08-26

Expected to finish

2017-11-27

Last updated by the study team

2024-12-13

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Anniston, Alabama, United States
• Research Site — Birmingham, Alabama, United States
• Research Site — Danbury, Connecticut, United States
• Research Site — DeBary, Florida, United States
• Research Site — Jacksonville, Florida, United States
• Research Site — Miami Springs, Florida, United States
• Research Site — Duncansville, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.